Dongxu MBA - CanSino Biologics Exec CoFounder

All Insiders . USA . 
Stock . CanSino Biologics . Stakeholders . Insider . Dongxu MBA
CASBF Stock  USD 3.88  0.12  3.00%   

Insider

Dongxu MBA is Exec CoFounder of CanSino Biologics
Age 62
Phone400 922 2099
Webhttps://www.cansinotech.com

CanSino Biologics Management Efficiency

The company has return on total asset (ROA) of (0.0207) % which means that it has lost $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0111 %, meaning that it generated $0.0111 on every $100 dollars invested by stockholders. CanSino Biologics' management efficiency ratios could be used to measure how well CanSino Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
CanSino Biologics has accumulated 40 M in total debt with debt to equity ratio (D/E) of 0.26, which may suggest the company is not taking enough advantage from borrowing. CanSino Biologics has a current ratio of 2.93, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist CanSino Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, CanSino Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CanSino Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CanSino to invest in growth at high rates of return. When we think about CanSino Biologics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jonathan TostoCanopy Growth Corp
N/A
Rick SavoneAurora Cannabis
N/A
Ryan HellardSNDL Inc
36
Terry YanofskyCanopy Growth Corp
N/A
Theresa YanofskyCanopy Growth Corp
63
Thomas LarssenAurora Cannabis
N/A
Shayne LaidlawCronos Group
N/A
Thomas StewartCanopy Growth Corp
42
Robbie MadanSNDL Inc
45
James SabiaCanopy Growth Corp
59
Thomas ShipleyCanopy Growth Corp
30
Carlos CortezCronos Group
51
John BarnetAurora Cannabis
N/A
Julious GrantCanopy Growth Corp
56
Michael DetlefsenAurora Cannabis
56
Lance FriedmannAurora Cannabis
65
William NewlandsCanopy Growth Corp
62
Zachary IVSNDL Inc
47
Jimes SabiaCanopy Growth Corp
58
Theresa FirestoneAurora Cannabis
65
Kevin GiffordCronos Group
N/A
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2191 people. CanSino Biologics [CASBF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.0111
Return On Asset-0.0207

CanSino Biologics Leadership Team

Elected by the shareholders, the CanSino Biologics' board of directors comprises two types of representatives: CanSino Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CanSino. The board's role is to monitor CanSino Biologics' management team and ensure that shareholders' interests are well served. CanSino Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CanSino Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Yonghui Wu, VP Marketing
Xuefeng Yu, Chairman, CoFounder
Tao Zhu, Ex CoFounder
Chunlin Xin, Director Department
Xi Luo, Chief Officer
FCS FCIS, Joint Sec
Dongxu MBA, Exec CoFounder
Jing Wang, Deputy Officer
ShouBai Chao, COO Director

CanSino Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CanSino Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0111
Return On Asset-0.0207
Profit Margin0.06 %
Operating Margin(0.19) %
Current Valuation3.58 B
Shares Outstanding114.78 M
Shares Owned By Insiders26.70 %
Shares Owned By Institutions38.17 %
Price To Earning19.25 X
Price To Book2.30 X

Currently Active Assets on Macroaxis

BTCBitcoin
TRXTRON
BNBBinance Coin
ADACardano
XRPXRP

Other Information on Investing in CanSino Pink Sheet

CanSino Biologics financial ratios help investors to determine whether CanSino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY